Contineum Therapeutics In... (CTNM)
| Bid | 4.05 |
| Market Cap | 106.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.26M |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | -1.89 |
| Forward PE | -1.52 |
| Analyst | Buy |
| Ask | 4.38 |
| Volume | 135,127 |
| Avg. Volume (20D) | 65,043 |
| Open | 4.18 |
| Previous Close | 3.97 |
| Day's Range | 3.94 - 4.27 |
| 52-Week Range | 3.69 - 22.00 |
| Beta | 0.70 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Th...
Analyst Forecast
According to 4 analyst ratings, the average rating for CTNM stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 483.94% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS ForumSAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
